Sign In
Buy IMGN
$31.23
+0 (+0%)
At Close: May 08, 2024
ImmunoGen (IMGN) Q3 Earnings and Revenues Top Estimates
09:01am, Thursday, 02'nd Nov 2023
ImmunoGen (IMGN) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.31 per share a year ago.
Analyzing The Acquisition Potential Of ImmunoGen
03:25pm, Tuesday, 31'st Oct 2023
ImmunoGen, Inc.'s marketing authorization application for ELAHERE, a cancer therapy, has been accepted by the EMA. Rumors suggest that large European pharma companies, including GSK, Sanofi, or Merck,
Top Medical Stocks to Buy Amid Recent Market Volatility
07:33pm, Monday, 23'rd Oct 2023
Several Zacks Medical sector stocks were recently added to the Zacks Rank #1 (Strong Buy) list over the last week and should be viable options for investors during economic uncertainty as healthcare i
New Strong Buy Stocks for October 20th
08:16am, Friday, 20'th Oct 2023
OSCR, IMGN, AFRM, ACVA and SOLO have been added to the Zacks Rank #1 (Strong Buy) List on October 20, 2023.
3 Solid Stocks to Buy for Superb Earnings Acceleration
07:31am, Wednesday, 18'th Oct 2023
Invest in stocks such as Catalyst Pharmaceuticals (CPRX), ImmunoGen (IMGN) and Inari Medical (NARI) for solid earnings acceleration.
New Strong Buy Stocks for October 18th
07:31am, Wednesday, 18'th Oct 2023
MRO, APA, IMGN, RAIL and MFA have been added to the Zacks Rank #1 (Strong Buy) List on October 18, 2023.
4 Stocks That Exhibit Solid Earnings Acceleration
09:01am, Friday, 06'th Oct 2023
Invest in stocks like Catalyst Pharmaceuticals (CPRX), ImmunoGen (IMGN), Inari Medical (NARI) and Kyndryl Holdings (KD) for superb earnings acceleration.
3 Examples of How Moneyness Impacts Options Trading
02:39pm, Friday, 01'st Sep 2023
Subscribers to Chart of the Week received this commentary on Sunday, August 27.
ImmunoGen: Takeda Swoops For Slice Of Elahere - Adding To Valuation Uncertainty?
01:45pm, Tuesday, 29'th Aug 2023
Yesterday, ImmunoGen, Inc. announced it has entered an exclusive licensing agreement with Takeda for the rights to develop and commercialize Mirvetuximab Soravtansine in the Japanese market. ImmunoGen
ImmunoGen stock jumps after licensing deal with Japan's Takeda Pharmaceutical
06:50am, Monday, 28'th Aug 2023
Shares of ImmunoGen Inc. IMGN, +1.45% jumped 1.7% in premarket trading Monday, after the Massachusetts-based drug maker announced a collaboration with Takeda Pharmaceutical Co. Ltd. TAK, +0.59% 4502,
These Are the ONLY 3 Biotech Stocks to Consider in August 2023
04:20pm, Monday, 21'st Aug 2023
The world may be on the mend from the grip of the global pandemic, but the consistent drumbeat for medical innovation remains as unyielding as ever. Amid this backdrop, Biotech stocks present a beacon
Options Bears Break Bank With Biotech Stock Puts
03:11pm, Tuesday, 08'th Aug 2023
Subscribers to Schaeffer's Event Trader service scored a 272% profit with our ImmunoGen, Inc. (NASDAQ:IMGN) August 17 put recommendation.
ImmunoGen (IMGN) Reports Q2 Loss, Tops Revenue Estimates
09:38am, Monday, 31'st Jul 2023
ImmunoGen (IMGN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.24 per share a year ago.
ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2023 Operating Results
04:01pm, Monday, 17'th Jul 2023
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will ho
ImmunoGen (IMGN) Crossed Above the 20-Day Moving Average: What That Means for Investors
11:18am, Monday, 17'th Jul 2023
ImmunoGen (IMGN) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, IMGN broke through the 20-day moving average, which suggests a shor
